Physicians discuss the basics of NET diagnosis, classification, and progression. Particular attention is paid to the frequency of misdiagnosis. Two patients share their stories of delayed NET diagnosis and treatment due to the misidentification of symptoms.
FDA approves Gallium-68 DOTATOC PET/CT, another new imaging agent, for use in scanning neuroendocrine tumors. Data showed Gallium-68 DOTATOC superior to decades-old methods for disease staging, treatment planning, and identifying unknown primary sites.
NETRF’s Aretha Franklin Fund for Neuroendocrine Cancer Research established with a gift from Women’s Informal Network, Detroit.